As Japanese drugmaker Eisai this week presented data confirming it had developed the first drug to slow cognitive decline in Alzheimer’s patients, the audience at a conference in San Francisco burst into applause.
Among those in attendance was Lars Lannfelt, a little-known Swedish scientist who invented the groundbreaking drug, known as lecanemab, and will make a fortune if it is approved and successfully marketed.
BioArctic, the company he co-founded in 2003 with Pär Gellerfors, struck a licensing deal on the monoclonal antibody therapy with Eisai in 2007, entitling it to hundreds of millions of dollars in milestone payments and royalties on lecanemab sales.
您已阅读10%（665字），剩余90%（5811字）包含更多重要信息，订阅以继续探索完整内容，并享受更多专属服务。